0J9P Stock Chart & Stats
$119.17
$1.20(1.02%)
At close: 4:00 PM EDT
$119.17
$1.20(1.02%)
Day’s Range― - ―
52-Week Range$81.50 - $134.25
Previous CloseN/A
Volume2.68K
Average Volume (3M)1.32K
Market Cap
$24.36B
Enterprise Value$19.11K
Total Cash (Recent Filing)$4.54B
Total Debt (Recent Filing)$38.27M
Price to Earnings (P/E)14.8
Beta0.72
Next Earnings
Nov 03, 2026EPS Estimate
-2.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.13
Shares Outstanding202,697,740
10 Day Avg. Volume979
30 Day Avg. Volume1,320
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.73
Price to Sales (P/S)3.75
P/FCF Ratio14.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$128.50Price Target Upside7.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)4.18
Revenue Forecast (FY)$5.91B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Minimal DebtMinimal debt (debt-to-equity ~0.5%) and an expanded equity base give Incyte substantial financial flexibility to fund launches, sustain multi-year R&D, and pursue M&A without adding leverage. Low structural indebtedness reduces refinancing and solvency risk over the medium term.
Strong Cash Generation And High MarginsVery high TTM gross and operating margins plus robust operating cash flow (~$2.0B) and FCF (~$1.9B) create durable internal funding for pipeline development and launches. Strong cash conversion supports strategic optionality and reduces reliance on external financing across several years.
Pipeline Diversification And Strategic M&AThe Vega acquisition (VGA039 Phase 3) plus multiple late‑stage programs, regulatory submissions and recent Opzelura EU approval materially broaden Incyte’s commercial footprint. These structural moves diversify revenue away from Jakafi and build durable hematology and dermatology franchises.
Bears Say
Revenue Concentration In JakafiJakafi remains the single largest revenue driver, implying material concentration risk. Until new launches and acquired assets scale, adverse competitive, reimbursement, or safety developments affecting Jakafi would materially reduce revenue predictability and cash flow resilience.
Sustained Elevated R&D And Operating SpendOngoing heavy investment in late‑stage trials and launch readiness improves long‑term prospects but structurally raises cash burn and pressures GAAP profitability. Success of multiple programs is required to justify sustained spend; execution shortfalls would strain margins and cash deployment plans.
Safety Signal And Trial/approval Timing Risk (734)Reported pneumonitis cases and an administrative hold introduce regulatory scrutiny and execution risk for the 734 program. Safety-driven delays or additional monitoring obligations can extend timelines, increase costs, and affect eventual label/market access for a material oncology candidate.
Incyte News
0J9P FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest share price was $81.50 and its highest was $134.25 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is $24.36B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Nov 03, 2026 which is in 79 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Jul 28, 2026. The company reported $3.09 earnings per share for the quarter, beating the consensus estimate of $2.196 by $0.894.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Incyte Corp dividends here
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is -2.78.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 202,697,740 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $3.09 in its last earnings report, beating expectations of $2.196. Following the earnings report the stock price went up 8.925%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in GB:0J9P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$128.50 (7.83% Upside)
$128.50 (7.83% Upside)
Blogger Sentiment
Bullish
GB:0J9P Sentiment 82%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $18.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.24%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
0J9P Company Deck
0J9P Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful pipeline maturation: double-digit and multi-factor sales growth (notably Opzelura and core products), multiple regulatory milestones and new Phase III starts, a strategic acquisition adding a high-potential hematology asset, and an upward revision to full-year revenue guidance. Offsetting these positives are reliance on a one-time CMS settlement that materially boosted near-term results and guidance, the discontinuation of the 058 JAK2 program, and materially higher near-term operating expenses driven by acquisition-related charges and expanded late-stage investments. Management emphasized execution risk, reimbursement dynamics and regulatory discussions that remain unresolved for some programs. Overall, the highlights — broad commercial growth, pipeline progression and strengthened late-stage portfolio — outweigh the lowlights, though near-term margin and execution risks merit monitoring.View all GB:0J9P earnings summaries0J9P Revenue Breakdown
84.69% Product revenues, net
12.39% Product royalty revenues
2.92% Milestone and contract revenues
0J9P Stock 12 Month Forecast
Average Price Target
$128.50
▲(7.83% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
United Therapeutics
―
Ascendis Pharma
―
Genmab
―